D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea · Delayed Price · Currency is KRW 80,800
+3,300 (4.26%)
Feb 9, 2026, 9:18 AM KST
D&D Pharmatech Revenue
D&D Pharmatech had revenue of 969.49M KRW in the quarter ending September 30, 2025, a decrease of -50.02%. This brings the company's revenue in the last twelve months to 8.36B, up 2.15% year-over-year. In the year 2024, D&D Pharmatech had annual revenue of 11.44B, down -38.77%.
Revenue (ttm)
8.36B
Revenue Growth
+2.15%
P/S Ratio
403.45
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.37T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.44B | -7.24B | -38.77% |
| Dec 31, 2023 | 18.68B | 18.07B | 2,958.97% |
| Dec 31, 2022 | 610.57M | -753.54M | -55.24% |
| Dec 31, 2021 | 1.36B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.20T |
| SK Biopharmaceuticals | 675.41B |
| SK bioscience | 624.03B |
| PharmaResearch | 496.03B |
| Hugel | 404.19B |
| LigaChem Biosciences | 159.27B |
| HLB Co., Ltd. | 80.73B |
| OliX Pharmaceuticals | 10.18B |